ATE395061T1 - Topische zusammensetzungen zur transdermalen gabe von niacin prodrugs sowie verfahren zur behandlung von hyperlipidämie - Google Patents

Topische zusammensetzungen zur transdermalen gabe von niacin prodrugs sowie verfahren zur behandlung von hyperlipidämie

Info

Publication number
ATE395061T1
ATE395061T1 AT01930535T AT01930535T ATE395061T1 AT E395061 T1 ATE395061 T1 AT E395061T1 AT 01930535 T AT01930535 T AT 01930535T AT 01930535 T AT01930535 T AT 01930535T AT E395061 T1 ATE395061 T1 AT E395061T1
Authority
AT
Austria
Prior art keywords
methods
transdermal administration
topical compositions
treating hyperlipidemia
niacin
Prior art date
Application number
AT01930535T
Other languages
English (en)
Inventor
Myron Jacobson
Hyuntae Kim
Moonsun Kim
Elaine Jacobson
Jaber Qasem
Original Assignee
Niadyne Corp
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22730106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE395061(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Niadyne Corp, Univ Kentucky Res Found filed Critical Niadyne Corp
Application granted granted Critical
Publication of ATE395061T1 publication Critical patent/ATE395061T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT01930535T 2000-04-14 2001-04-16 Topische zusammensetzungen zur transdermalen gabe von niacin prodrugs sowie verfahren zur behandlung von hyperlipidämie ATE395061T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19762100P 2000-04-14 2000-04-14

Publications (1)

Publication Number Publication Date
ATE395061T1 true ATE395061T1 (de) 2008-05-15

Family

ID=22730106

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01930535T ATE395061T1 (de) 2000-04-14 2001-04-16 Topische zusammensetzungen zur transdermalen gabe von niacin prodrugs sowie verfahren zur behandlung von hyperlipidämie

Country Status (14)

Country Link
US (1) US6677361B2 (de)
EP (1) EP1274429B1 (de)
JP (1) JP4156841B2 (de)
CN (1) CN1430513B (de)
AT (1) ATE395061T1 (de)
AU (2) AU2001257063B2 (de)
CA (1) CA2441461C (de)
DE (1) DE60134002D1 (de)
DK (1) DK1274429T3 (de)
ES (1) ES2302732T3 (de)
HK (1) HK1053607A1 (de)
MX (1) MXPA02010184A (de)
PT (1) PT1274429E (de)
WO (1) WO2001078727A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6464992B2 (en) * 2000-04-14 2002-10-15 University Of Kentucky Research Foundation Topical micronutrient delivery system and uses thereof
US20040081672A1 (en) * 2002-10-25 2004-04-29 Gupta Shyam K. Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging
US20040191278A1 (en) * 2003-03-31 2004-09-30 Christensen Flemming Kjaergaar Topical agent for application to the skin prior to luminous treatment
US20040254202A1 (en) * 2003-06-13 2004-12-16 The Procter & Gamble Company Method of promoting sleep using topical administration of vasoactive agents
US20050267091A1 (en) * 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses
AU2008219633B2 (en) * 2007-02-28 2011-05-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Method for alleviating side effects of retinoic acid therapy and/or improving efficacy without interfering with efficacy
US20100292280A1 (en) * 2007-04-15 2010-11-18 Oron Zachar Anti-pyretic vasodilators
CN102532114B (zh) * 2011-12-19 2016-08-03 中山大学 烟酸衍生物,其制备方法及其药物组合物
CA2947308A1 (en) 2013-05-09 2014-11-13 Zeenar Enterprises Pty Ltd Niacin formulation
AU2015270090A1 (en) 2014-06-06 2016-12-22 Glaxosmithkline Intellectual Property (No.2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
WO2019046735A1 (en) * 2017-08-31 2019-03-07 Lonza Inc. HEALTH PROMOTING COMPOSITION AND METHODS OF USING COMPLEMENT-RELATED APPLICATIONS
WO2019121529A1 (en) 2017-12-18 2019-06-27 Unilever N.V. A topical composition
MX2020006280A (es) * 2017-12-18 2021-11-12 Unilever Ip Holdings B V Una composición tópica basada en un derivado de niacinamida.
US11767314B2 (en) 2018-11-02 2023-09-26 Conopco, Inc. Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1046055B (de) * 1956-06-18 1958-12-11 Ernst Schneider Dipl Chem Dr Verfahren zur Herstellung eines Esters mehrfach ungesaettigter hoehermolekularer Fettsaeuren
EP0182635B1 (de) * 1984-11-15 1989-05-31 Nitto Denko Corporation Zusammensetzung zur perkutanen Anwendung
GB2210789A (en) * 1987-10-10 1989-06-21 Morrison Dr Ian Donald Topical application for skin care
WO1989005626A1 (fr) * 1987-12-24 1989-06-29 Fujisawa Pharmaceutical Co., Ltd. Agent stimulant la croissance des cheveux
EP2319513A1 (de) * 1993-09-20 2011-05-11 Abbott Respiratory LLC Nikotinsäurezusammensetzungen zur Behandlung von Hyperlipidämie und zugehörige Verfahren dafür
US5496827A (en) 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
AU5787996A (en) * 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
EP0823897B1 (de) * 1995-05-01 2004-07-28 Scarista Limited Nicotinsäureester und diese enthaltende pharmazeutischen zusammensetzungen
GB9610971D0 (en) * 1996-05-29 1996-07-31 Scotia Holdings Plc A diagnostic test for use in schizophrenia
WO1998052927A1 (en) * 1997-05-19 1998-11-26 Rosemarie Scivoletto Composition for treating skin conditions
DE69919403T2 (de) * 1998-12-01 2005-09-08 The University Of Kentucky Research Foundation Verwendung von nikotinsäurederivate zur behandlung von dna-schäden bei hautzellen
US6464992B2 (en) * 2000-04-14 2002-10-15 University Of Kentucky Research Foundation Topical micronutrient delivery system and uses thereof

Also Published As

Publication number Publication date
CN1430513B (zh) 2010-12-08
AU5706301A (en) 2001-10-30
AU2001257063B2 (en) 2005-04-28
MXPA02010184A (es) 2004-08-19
PT1274429E (pt) 2008-06-17
HK1053607A1 (en) 2003-10-31
JP2004500428A (ja) 2004-01-08
JP4156841B2 (ja) 2008-09-24
CN1430513A (zh) 2003-07-16
US20010049382A1 (en) 2001-12-06
ES2302732T3 (es) 2008-08-01
EP1274429A4 (de) 2006-03-01
WO2001078727A1 (en) 2001-10-25
EP1274429A1 (de) 2003-01-15
DK1274429T3 (da) 2008-08-25
DE60134002D1 (de) 2008-06-26
US6677361B2 (en) 2004-01-13
CA2441461C (en) 2007-07-10
WO2001078727A8 (en) 2003-11-27
EP1274429B1 (de) 2008-05-14
CA2441461A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
ATE395061T1 (de) Topische zusammensetzungen zur transdermalen gabe von niacin prodrugs sowie verfahren zur behandlung von hyperlipidämie
DE60136348D1 (de) Topische zusammensetzung zur behandlung von psoriasis und verwandten hautkrankheiten
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
PT1239849E (pt) Formulacoes farmaceuticas que compreendem resveratrol e a sua utilizacao
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
ATE361084T1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
NO20071742L (no) Kinazoliner som er nyttige som modulatorer av ionekanaler
HRP20050633A2 (en) Formulation and methods for the treatment of thrombocythemia
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
DK0699439T3 (da) Behandling af sygdomme forårsaget af talgkirtellidelser med acyl-CoA-cholesterolacyltransferaseinhibitorer
BR0308957A (pt) Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparação
ATE474572T1 (de) Heilung von wunden
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
DK1638582T3 (da) Anvendelse af hyaluronsyre til fremstilling af kompositioner til behandling af tilbagevendende after
IL190850A (en) Use of Artemisinin and Derivatives to Prepare a Pharmacist and Insulin Composition Containing Local Compositions Containing Them
DE69927260D1 (de) Topische pharmazeutische zusammensetzung zur behandlung von haut- oder zirkulatorischen krankheiten auf inflammatorischer, immun-, proliferativer oder degenerativer basis
WO2004030623A3 (en) Nitroxide radioprotector formulations and methods of use
DK1594456T3 (da) Anvendelse af en sammensætning indeholdende vitamin K1-oxid eller et derivat deraf til behandling og/eller forebyggelse af dermatologiske læsioner hos pattedyr
SE0203817D0 (sv) New composition
IT1265647B1 (it) Composizione farmaceutiche topiche per le allergie respiratorie
NO20030483D0 (no) Assosiasjoner av dalfopristin/quinupristin med cefpirom
AU8900498A (en) Compounds and pharmaceutical compositions thereof for eliciting analgesic effects

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1274429

Country of ref document: EP